Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

ABSTRACT: Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

PROVIDER: PRJNA215007 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Project description:<p>This is a prospective, multicenter, randomized, open-label, parallel-group study to evaluate pharmacogenomic responses to antihypertensives. The primary aim of this study is to identify the genetic determinants of antihypertensive and adverse metabolic responses focused on two preferred and pharmacodynamically contrasting drugs, a beta-blocker (atenolol) and a thiazide diuretic (HCTZ) given initially as monotherapy, and subsequently in combination, to 768 individuals with uncomplicated hypertension. This includes assessment of genetic associations with: antihypertensive responses to monotherapy, addition of a second drug to monotherapy, and combination therapy; and adverse metabolic responses to mono and combination therapy. High quality phenotype data, including both home and ambulatory measures of blood pressure response, and lipid and insulin sensitivity measures of adverse metabolic responses were collected. DNA samples were plated into 96-well plates and included a 2% sample replication for QC and a Caucasian parent-child CEPH trio from the HapMap project to check for Mendelian transmission of alleles. Genotypes were determined with the Illumina HumanOmni1-Quad and HumanCVD BeadChip.</p>

| phs000649 | dbGaP

Homo sapiens

Project description:Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

| PRJNA215008 | ENA

Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.